CVAC - CureVac N.V.

3.47
0.240   6.916%

Share volume: 687,704
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$3.23
0.24
0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
6.44%
1 Month
25.27%
3 Months
-10.34%
6 Months
20.07%
1 Year
37.70%
2 Year
-50.43%
Key data
Stock price
$3.47
P/E Ratio 
0.00
DAY RANGE
$3.27 - $3.59
EPS 
N/A
52 WEEK RANGE
$2.37 - $5.28
52 WEEK CHANGE
$37.70
MARKET CAP 
702.983 M
YIELD 
N/A
SHARES OUTSTANDING 
223.880 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-22-2025
BETA 
1.21
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$430,034
AVERAGE 30 VOLUME 
$618,765
Company detail
CEO: Franz-Werner Haas
Region: US
Website: curevac.com
Employees: 880
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CureVac N.V. focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA) It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV and CV7202. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma.

Recent news
loading